MX2022012229A - Composiciones de anticuerpo anti cd6 y metodos para tratar y reducir efectos negativos de un coronavirus incluyendo a covid 19. - Google Patents

Composiciones de anticuerpo anti cd6 y metodos para tratar y reducir efectos negativos de un coronavirus incluyendo a covid 19.

Info

Publication number
MX2022012229A
MX2022012229A MX2022012229A MX2022012229A MX2022012229A MX 2022012229 A MX2022012229 A MX 2022012229A MX 2022012229 A MX2022012229 A MX 2022012229A MX 2022012229 A MX2022012229 A MX 2022012229A MX 2022012229 A MX2022012229 A MX 2022012229A
Authority
MX
Mexico
Prior art keywords
treating
methods
negative effects
antibody compositions
reducing negative
Prior art date
Application number
MX2022012229A
Other languages
English (en)
Inventor
Pradip Nair
Monzón Kalet León
Jose Enrique Montero Casimiro
Shaw Kiran Mazumdar
Usha Bughani
Sandeep Nilkanth Athalye
Melarkode Subbaraman Ramakrishnan
Ramos Tania Crombet
Suzarte Mayra Ramos
Original Assignee
Biocon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CU2020000027A external-priority patent/CU20200027A7/es
Application filed by Biocon Ltd filed Critical Biocon Ltd
Publication of MX2022012229A publication Critical patent/MX2022012229A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona el uso de anticuerpos anti-CD6 que se unen específicamente al dominio 1 de CD6 para tratar efectos de un coronavirus o agente bacteriano y particularmente COVID-19 y variantes del mismo. Los anticuerpos anti-CD6 de la presente invención presentan actividad terapéutica al reducir la respuesta inmunitaria hiperreactiva, como por ejemplo los altos niveles de expresión de citosinas.
MX2022012229A 2020-04-04 2021-04-03 Composiciones de anticuerpo anti cd6 y metodos para tratar y reducir efectos negativos de un coronavirus incluyendo a covid 19. MX2022012229A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202041014994 2020-04-04
CU2020000027A CU20200027A7 (es) 2020-04-17 2020-04-17 Uso de anticuerpos monoclonales anti-cd6 no depletantes en el tratamiento de la tormenta de citocinas
PCT/IB2021/052793 WO2021199006A1 (en) 2020-04-04 2021-04-03 Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19

Publications (1)

Publication Number Publication Date
MX2022012229A true MX2022012229A (es) 2022-10-27

Family

ID=77928142

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012229A MX2022012229A (es) 2020-04-04 2021-04-03 Composiciones de anticuerpo anti cd6 y metodos para tratar y reducir efectos negativos de un coronavirus incluyendo a covid 19.

Country Status (15)

Country Link
US (1) US20230151107A1 (es)
EP (1) EP4126961A4 (es)
JP (1) JP2023526890A (es)
KR (1) KR20220165267A (es)
CN (1) CN115698071A (es)
AU (1) AU2021247258A1 (es)
BR (1) BR112022018936A2 (es)
CA (1) CA3174566A1 (es)
CL (1) CL2022002684A1 (es)
CO (1) CO2022014199A2 (es)
IL (1) IL296487A (es)
MX (1) MX2022012229A (es)
TW (1) TW202200202A (es)
WO (1) WO2021199006A1 (es)
ZA (1) ZA202210032B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0822447A2 (pt) 2008-03-14 2015-06-16 Biocon Ltd Anticorpo monoclonal e método do mesmo

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0822447A2 (pt) * 2008-03-14 2015-06-16 Biocon Ltd Anticorpo monoclonal e método do mesmo
CA3091920A1 (en) * 2018-02-27 2019-09-06 Equillium, Inc. Anti cd6 antibodies for treating severe asthma
MX2022007911A (es) * 2019-12-24 2022-07-21 Hoffmann La Roche Procedimiento de tratamiento de una infeccion virica usando un agonista de tlr7.

Also Published As

Publication number Publication date
WO2021199006A1 (en) 2021-10-07
AU2021247258A1 (en) 2022-11-10
EP4126961A4 (en) 2024-07-17
TW202200202A (zh) 2022-01-01
BR112022018936A2 (pt) 2022-12-06
JP2023526890A (ja) 2023-06-26
EP4126961A1 (en) 2023-02-08
ZA202210032B (en) 2024-09-25
CA3174566A1 (en) 2021-10-07
KR20220165267A (ko) 2022-12-14
CN115698071A (zh) 2023-02-03
CL2022002684A1 (es) 2023-03-24
CO2022014199A2 (es) 2022-11-08
IL296487A (en) 2022-11-01
US20230151107A1 (en) 2023-05-18

Similar Documents

Publication Publication Date Title
CR20220363A (es) Compuestos tricíclicos sustituidos
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
MX2021009521A (es) Inhibidores de dihidroorotato deshidrogenasa.
MX2022001004A (es) Inhibidores de enzimas.
MX2021016049A (es) Metodos de uso de inhibidores de rad51 para el tratamiento de cancer de pancreas.
CR20210103A (es) Composición farmacéutica para usarse en el tratamiento o prevención de una enfermedad relacionada con c5 y método para tratar o prevenir una enfermedad relacionada con c5
MX2021015156A (es) Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, y metodos de uso de estos.
MX2022010944A (es) Inhibidores del factor de iniciacion de traduccion eucariotica 4e (eif4e) y sus usos.
MX2023001564A (es) Terapias genicas para trastornos neurodegenerativos.
MX2020008991A (es) Metodos para alterar la composicion corporal.
ZA202210032B (en) Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
MX2023012325A (es) Anticuerpos anti-tslp modificados.
MX2022000811A (es) Inhibidores de enzimas.
JOP20220204A1 (ar) الأجسام المضادة لـ cd19 البشرية
WO2021158635A8 (en) Anti-viral compositions and methods of use
JOP20210245A1 (ar) طرق لعلاج الداء النشواني من النوع خفيف السلسلة
MX2022002069A (es) Inhibidores de enzimas.
MX2023006231A (es) Inhibidores de enzimas.
WO2022169961A8 (en) Sigma receptor ligands for treating sars-cov-2 infection
MX2022012404A (es) Composiciones que comprenden 15-hepe para tratar o prevenir trastornos hematológicos y/o enfermedades relacionadas.
MX2021005751A (es) Anticuerpos contra mucina 16 y métodos de uso de los mismos.
MX2024001954A (es) Anticuerpos il-13 para el tratamiento de la dermatitis atopica.
MX2023006704A (es) Composiciones dsg2 y metodos para el tratamiento de covid-19.
ZA202205813B (en) Trpv1 epitopes and antibodies
MX2023010812A (es) Composiciones y metodos para tratar la nefritis lupica.